Alder BioPharmaceuticals of Bothell priced its initial public offering of stock at $10, below the expected range of $13 to $15.
Alder shares, listed on Nasdaq under the ticker ALDR, closed up 3 cents at $10.03 in their trading debut Thursday.
The offering raised $80 million before expenses for the biotech company, which is testing two drug candidates it developed — one to prevent migraines and one to treat rheumatoid arthritis and psoriatic arthritis.
Alder filed its IPO plans in mid-March, when biotech deals were booming. But investor enthusiasm for the sector has cooled, with the Nasdaq biotechnology index down more than 14 percent since March 18.
- Could Chris Polk be a fit for the Seahawks?
- Jesse Jones is back: Seattle's superhero consumer reporter is now at KIRO 7
- Nathan Hale High School juniors boycott state test
- This USB cable finally could be connector for long haul
- Scientists to study the 'modern miracle' of Ozzy Osbourne's survival